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ABSTRACT
Background Of the newer antiepileptic drugs,
lamotrigine (LTG) and levetiracetam (LEV) are popular
first choice drugs for epilepsy. The authors compared
these drugs with regard to their efficacy and tolerability
in the initial monotherapy for epilepsy.
Methods A randomised, open-label, controlled, parallel
group, multicenter trial was conducted to test the
superiority of the LEV arm over the LTG arm. The primary
endpoint was the rate of seizure-free patients in the first
6 weeks (two-sided Fisher’s exact test, a¼0.05, intent-to-
treat set). Furthermore, efficacy, tolerability and quality of
life were evaluated. The authors included 409 patients
aged$12 years with newly diagnosed focal or generalised
epilepsy defined by either two or more unprovoked
seizures or one first seizure with high risk for recurrence.
Patients were titrated to 2000 mg/day of LEV or 200 mg/
day of LTG reached on day 22 or 71, respectively. Two
dose adjustments by 500/50 mg were allowed.
Results The proportions of seizure-free patients were
67.5% (LEV) versus 64.0% (LTG) 6 weeks after
randomisation (p¼0.47), and 45.2% (LEV) versus 47.8%
(LTG) during the whole treatment period of 26 weeks.
The HR (LEV vs LTG) for seizure-free time was 0.86 (95%
CI, 0.61 to 1.22). Adverse events occurred in 74.5% (LEV)
versus 70.6% (LTG) of the patients (p¼0.38). Adverse
events associated with study discontinuation occurred in
17/204 (LEV) versus 8/201 (LTG) patients (p¼0.07).
Conclusions There were no significant differences with
regard to efficacy and tolerability of LEV and LTG in newly
diagnosed focal and generalised epilepsy despite more
rapid titration in the LEV arm.
Clinical trial registration number ClinicalTrials.gov
identifier NCT00242606.
INTRODUCTION
Epilepsy is a chronic neurological disorder with
a prevalence of about 0.5% and incidence rates of 70
per 100 000 in children and adolescents, 30 per
100 000 in adults aged 20e64 years and 100 per
100 000 in older people aged 65 years and older.1 In
$20% of newly diagnosed patients, the epilepsy
syndrome is unknown when treatment is initi-
ated.2 At the same time, these patients are likely to
take the initial monotherapy for a prolonged period
of time because it will render about 50% of them
seizure free3 4 while discontinuing the medication
will increase the risk of recurrence by about 50%.5 6
The choice of the initial antiepileptic drug (AED) is,
therefore, of great importance and, ideally, it should
have high and broad spectrum efﬁcacy as well as
good short- and long-term tolerability and safety,
have the ability to be rapidly titrated to effective
doses, and have no or little interactions with other
drugs or metabolism in general. The Standard and
New Antiepileptic Drug-trial (SANAD) investiga-
tors concluded that lamotrigine (LTG) is the drug of
ﬁrst choice in focal epilepsies because it showed the
highest long-term retention rate.7 In generalised or
unclassiﬁed epilepsy, LTG was less efﬁcacious than
valproic acid (VPA) but was equally well tolerated
and is still considered the drug of ﬁrst choice in
women of childbearing age, because of its relatively
low teratogenicity.8
The SANAD trial did not include levetiracetam
(LEV) which was ﬁrst marketed well after study
onset. LEV, however, rapidly gained wide accep-
tance because it has many pharmacokinetic char-
acteristics of an ideal AED. The compound is
approved in patients aged 1 month and older, can
be rapidly titrated and appears to be void of clini-
cally relevant pharmacokinetic interactions. Serious
adverse events (AEs) were rare but LEV does cause
relevant AEs such as tiredness and behavioural and
psychiatric disturbances.
Recent comparative trials have shown similar
efﬁcacy and tolerability in comparison with extended
release carbamazepine (CBZ)9 10 and VPA.10
Immediate seizure control will beneﬁt the
patient and society as it will lower epilepsy-related
costs, work absenteeism, stigma and reduce inter-
ference with quality of life (QoL) as well as the
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time to regain driving permission.11e13 Therefore, the possibility
of rapid titration is a potential advantage of LEV over LTG.
However, the two AEDs have not yet been directly compared in
a controlled prospective trial. We, therefore, conducted an active
comparator study to evaluate the efﬁcacy and tolerability of LEV
and LTG as initial treatment in patients aged 12 years or older
with newly diagnosed focal, generalised or unclassiﬁed epilepsy.
METHODS
Patients
Patients were eligible for the study if they were newly diagnosed
with focal, generalised or unclassiﬁed epilepsy deﬁned by either
two or more unprovoked seizures or one ﬁrst seizure with high
risk for recurrence, such as a lesion on cerebral imaging, a focal
neurological deﬁcit, based on ictal symptomatology, or a patho-
logical EEG (either interictal epileptiform discharges or focal
slowing).14 15 These inclusion criteria followed a recent proposal
for a revised deﬁnition of epilepsy.16 Patients with non-epileptic
seizures, auras or absences only, as well as patients with acute
symptomatic seizures (occurring within 14 days of an acute
brain injury such as a stroke), were excluded. We included
patients already receiving one AED at enrolment. Per protocol,
this AED was tapered off during the ﬁrst 3 weeks of the trial by
reducing the dose by one-quarter on days 1, 8, 15 and discon-
tinuing it on day 22. A complete list of the eligibility criteria is
provided in the online supplementary material.
The study protocol was approved by the relevant ethics
committees before patient enrolment commenced. All partici-
pants provided written informed consent before entering the
study. This trial was registered with http://ClinicalTrials.gov,
identiﬁer NCT00242606.
Study design and treatment
This was a randomised, open-label, active-controlled, parallel
group, multicenter monotherapy study. Recruitment was
performed by 58 board certiﬁed neurologists working either in
outpatient departments of hospitals or in private neurological
practices in Germany. Patients were randomised in a 1:1 ratio to
receive either LEV or LTG, both in normal (not in extended-
release) formulation, according to a computer-generated
balanced randomisation list. Stratiﬁcation criteria were age
(12e15 vs $16 years), type of epilepsy (generalised vs focal vs
not classiﬁed) and centre. Evaluations were performed at visits
after 4, 6, 11 and 26 weeks of treatment.
LEV was started with 500 mg/day and the dose was raised by
500 mg/week, while LTG was started with 25 mg and the dose
was initially increased by 25 mg/2 weeks and by 50 mg/2 weeks
once a daily dose of 100 mg was reached. Target daily doses of
2000 mg of LEV and 200 mg of LTG were to be achieved on day
22 and 71, respectively. In patients under the weight of 50 kg,
target daily doses were reduced to 1500 mg of LEVand 150 mg of
LTG. After reaching the target dose, two dose adjustments by
500 mg (LEV) or 50 mg (LTG) were allowed depending on
seizure control and tolerability. The entire treatment period per
patient was 26 weeks. Subsequently patients either remained on
LEV or LTG or were switched to another AED at the discretion
of their treating neurologists.
Study outcomes
The primary endpoint was seizure freedom in the ﬁrst 6 weeks
after randomisation, calculated as the rate of seizure-free patients
per group in the corresponding period. Secondary endpoints were
seizure freedom during the last 16 weeks of the trial and during
the complete treatment period calculated as the rate of seizure-
free patients between week 11 and the end of treatment, and
randomisation and the end of treatment, respectively.
Seizure-free time was calculated from randomisation to the
ﬁrst seizure documented during the treatment period of
26 weeks. Retention time was calculated as the interval from
randomisation to the regular end of treatment (26 weeks) or the
premature end of treatment.
The number and type of any seizure and AEs were docu-
mented using a patient-diary. AEs were documented according
to WHO criteria. QoL was assessed using the Quality of Life in
Epilepsy 10 (QOLIE-10) questionnaire, which has been shown to
discern differences among treatments in clinical trials,17 18 and
changes were calculated from baseline to the end of treatment.
Efﬁcacy, tolerability and QoL were evaluated at all visits. Blood
samples were collected initially before treatment was started, at
6 weeks and at the end of the study period to calculate creati-
nine clearance. Subgroup analyses were performed for patient
groups frequently considered separately in clinical trials or
management: patients aged 12e17 versus 18e59 versus
$60 years, patients with focal versus generalised or unclassiﬁed
epilepsy, and patients with a single seizure and high risk of
seizure recurrences versus those with two or more seizures.
These subgroups reportedly have different recurrence rates11 12
and were thought to potentially show different responses to the
two drugs tested. Data from a subset of 80 patients were
acquired for a pharmacoeconomic evaluation, the results of
which will be reported separately.
Statistical analysis
The study was designed to test for superiority of LEV over LTG
concerning the primary endpoint of seizure freedom in the ﬁrst
6 weeks of the trial. We estimated that 183 patients in each
treatment group were required to achieve 80% power (p¼0.05,
two-sided) to detect a clinically relevant difference of 15% in the
seizure-free patients’ rate, assuming a rate of 50% in the LTG
arm.19 With a dropout rate of 10%, 203 patients were required to
be randomised per group.
The analyses of seizure freedom in the ﬁrst 6 weeks, in the last
16 weeks and during the whole study were performed using
Fisher ’s exact tests, relative risks and risk differences in the
intent-to-treat (ITT) set including all patients randomised.
Premature discontinuation from the study without documented
seizure is a potential bias to the results, as a discontinuation
might have been caused by having experienced seizures. There-
fore, the following imputation strategy was applied: in the
primary analysis, patients who discontinued treatment before
week 6 were assumed to have had a seizure irrespective of
whether a seizure was documented during the study participa-
tion or not. In the analyses of the other seizure-free patients’
rates, discontinuation from treatment before week 24 was
assessed as due to seizure. Efﬁcacy outcomes were also analysed
in the per-protocol (PP) set, as deﬁned in the study protocol,
where patients with major protocol violations (patients falling
under the minimal weight, pretreatment >6 months, treatment
duration <24 weeks, deviation from target daily dose by more
than 1000 mg of LEV or 100 mg of LTG) were not considered.
The log-rank test was performed to compare the
KaplaneMeier estimates of seizure-free time and retention time,
and the unadjusted Cox proportional hazards model was used to
investigate the impact of study medication.
Differences between treatment groups in QoL were analysed
with the WilcoxoneManneWhitney test. Safety analyses were
based on the set of patients randomised who took at least one
dose of study medication. c2 Tests were performed to assess
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tolerability and safety (on the basis of the reported AEs), and in
the post-hoc subgroup analyses. All reported p values were two
sided. Statistical analyses were performed using the SAS statis-
tical package, V.9.1.3. The analyses of secondary endpoints and
of the post-hoc subgroups have to be considered as descriptive
statistics.
RESULTS
From March 2005 to October 2007, 409 patients (LEV¼206,
LTG¼203) were randomised in the study (ﬁgure 1). Baseline
demographic and clinical characteristics are given in table 1. All
patients randomised were included in the ITTanalysis (n¼409);
164 patients were considered protocol violators; consequently,
245 patients (LEV¼116, LTG¼129) remained for the PP analysis.
The results of all seizure-free rates are summarised in table 2.
The proportions of seizure-free patients at 6 weeks after
randomisation in the ITT set were 67.5% in the LEV arm and
64.0% in the LTG arm (p¼0.47). The chance for seizure freedom
after 6 weeks of treatment was increased by 5% (95% CI 8 to
21) in the LEVarm; the absolute difference was 3.4 (95% CI 5.8
to 12.6). In the PP set, seizure-free rates changed to 83.6% (LEV)
versus 79.8% (LTG) (p¼0.51). The proportions of seizure-free
patients during the last 16 weeks of the maintenance period in
the ITT set were 51.9% (LEV) and 55.7% (LTG) (p¼0.49), and
45.2% (LEV) and 47.8% (LTG) (p¼0.62) during the entire
26 weeks of the study.
The seizure-free time is given in ﬁgure 2. The median time to
ﬁrst seizure could not be calculated because the number of
events was insufﬁcient. There was no statistically signiﬁcant
difference between the two treatments (HR¼0.86, 95% CI 0.61
to 1.22, p¼0.40).
The retention rate did not differ signiﬁcantly between the
LEV and LTG arms (63.1% vs 71.4%; p¼0.07). Correspondingly,
the HR (LEV vs LTG) for the retention time was 1.34 (95% CI,
0.95 to 1.88, p¼0.10).
Assessment of QoL at the beginning of the treatment (LEV
mean: 2.5, SD: 0.9, n¼148; LTG mean: 2.5, SD: 0.9, n¼155) and
at the end of treatment (LEV mean: 2.2, SD: 0.9, n¼148; LTG
mean: 2.2, SD: 0.9, n¼155) was very similar in both treatment
groups. Consequently, changes in QoL (beginning to end of
treatment) were not signiﬁcantly different (p¼0.69).
Table 3 shows the most common AEs per group. AEs occurred
in 74.5% (LEV) versus 70.6% (LTG) of the patients (p¼0.38).
Tiredness and aggression occurred signiﬁcantly more often in the
LEVarm than in the LTG arm. Study discontinuation due to AEs
occurred not signiﬁcantly more frequently in the LEV arm (17/
204 patients) than in the LTG arm (8/201 patients; p¼0.07).
A total of 41 serious AEs in 35 patients were reported.
Seventeen serious AEs (in 15 patients) occurred in the LTG arm
and 24 (in 20 patients) in the LEV arm (p¼0.40). Most serious
AEs were not suspected to be related to study medications.
Post-hoc subgroup analysis
Efﬁcacy and tolerability of LEV and LTG were not signiﬁcantly
different in any of the subgroups analysed: patients aged 12e17
versus 18e59 versus $60 years; patients with focal versus
Figure 1 Patient disposition (as
recommended by the CONSORT 2010
statement). LEV, levetiracetam; LTG,
lamotrigine.
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generalised or unclassiﬁed epilepsy; patients with ﬁrst seizures
and a high risk of recurrence as compared with those with two
or more seizures.
However, seizure recurrences were less frequent in the older
patients (7/67, 10.5%) as compared with the young (11/33,
33.3%) and middle aged (76/309, 24.6%) patients (p¼0.02). The
same was true for the patients with a ﬁrst seizure and a high risk
of recurrence (11/85, 12.9%) as compared with those with
epilepsy (83/322, 25.8%; p¼0.01). On the contrary, the recur-
rence rates were similar for focal (54/212, 25.5%) versus gener-
alised or unclassiﬁed epilepsy (40/197, 20.3%, p¼0.21). The
proportion of patients taking an anticonvulsive drug at the time
of study enrolment did not signiﬁcantly differ between the
treatment arms (48/409; LEV 20/206, 9.7%; LTG 28/203, 13.2%;
p>0.05) nor show a group-dependent inﬂuence on the rate of
seizure recurrence during the study.
DISCUSSION
For the initial monotherapy in patients aged 12 years and older
with newly diagnosed focal, generalised or unclassiﬁed epilepsy,
we found no signiﬁcant differences between LEV and LTG with
respect to efﬁcacy, retention and tolerability, although LEV was
more rapidly introduced than LTG.
As reported previously,11 12 patients aged $60 years had
a signiﬁcantly lower rate of seizure recurrence than younger
patients, but due to small sample size the validity of this ﬁnding
is limited. Patients with single seizures in the setting of an
increased risk for seizure recurrence according to the proposed
new deﬁnition of epilepsy16 had a signiﬁcantly lower rate of
seizure recurrence than patients who had experienced two or
more epileptic seizures at randomisation.
While the seizure-free rate was somewhat higher at 6 weeks
after randomisation and while the time to seizure recurrence
was longer in the LEV arm, none of these differences reached
statistical signiﬁcance. It could not be shown, to our surprise,
that the possibility of a more rapid titration with LEV corre-
sponds to a reduction in seizure recurrence in patients with
newly diagnosed epilepsy. This may, in part, be due to the
characteristics of our population, which had a much lower rate
of seizure recurrence than estimated when calculating the
sample size needed, potentially due to the inclusion of 16% older
patients and 21% of patients after a ﬁrst seizure. We included
patients already receiving one AED at enrolment. Per protocol,
this AED was tapered off over the initial 3 weeks of the study
and discontinued by day 22. As the proportion of such patients
was low in both groups and did not signiﬁcantly differ between
treatment arms nor show a group-dependent inﬂuence on the
rate of seizure recurrence, it appears highly unlikely that the
overall results of the study were affected by the inclusion of such
Table 1 Baseline characteristics
Characteristic
Levetiracetam
(n[206)
Lamotrigine
(n[203)
Total
(n[409)
Age
Median (range) (years) 39.5 (12e84) 37.0 (13e80) 38.0 (12e84)
Age groups (years) n (%) n (%) n (%)
12e15 11 (5.3) 9 (4.4) 20 (4.9)
$16 195 (94.7) 194 (95.6) 389 (95.1)
12e17 17 (8.3) 16 (7.9) 33 (8.1)
18e59 154 (74.8) 155 (76.4) 309 (75.6)
$60 35 (17.0) 32 (15.8) 67 (16.4)
Sex
Female 92 (44.7) 102 (50.2) 194 (47.4)
Male 114 (55.3) 101 (49.8) 215 (52.6)
Weight groups (kg)
#50 10 (4.9) 8 (3.9) 18 (4.4)
>50 196 (95.1) 195 (96.1) 391 (95.6)
Epilepsy syndromes
Focal 104 (50.5) 108 (53.2) 212 (51.8)
Generalised 71 (34.5) 73 (36.0) 144 (35.2)
Not classifiable 31 (15.0) 22 (10.8) 53 (13.0)
First seizure versus epilepsy
First seizure 45 (21.8) 40 (19.7) 85 (20.8)
Epilepsy 161 (78.2) 161 (79.3) 322 (78.7)
Missing 0 (0.0) 2 (1.0) 2 (0.5)
Table 2 Seizure freedom rates
Levetiracetam, N (%) Lamotrigine, N (%)
Fisher’s
exact test RR (95% CI)
Risk difference
(95% CI)
ITT n[206 n[203
PP n[116 n[129
Primary endpoint
Seizure freedom after 6 weeks
ITT 139 (67.5) 130 (64.0) p¼0.47 1.05 (0.92 to 1.21) 3.4 (5.8 to 12.6)
PP 97 (83.6) 103 (79.8) p¼0.51 1.05 (0.93 to 1.18) 3.8 (5.9 to 13.4)
Secondary endpoints
Seizure freedom during the last 16 weeks (ITT) 107 (51.9) 113 (55.7) p¼0.49 0.93 (0.78 to 1.12) 3.7 (13.4 to 5.9)
Seizure freedom during the last 26 weeks (ITT) 93 (45.2) 97 (47.8) p¼0.62 0.94 (0.77 to 1.16) 2.6 (12.3 to 7.0)
ITT, intent-to-treat; PP, per-protocol.
Figure 2 Seizure-free time; levetiracetam (LEV) n¼206, lamotrigine
(LTG) n¼203.
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patients. The proportion of patients with protocol violations
was quite high at 40.1% (n¼165). Most of the patients were
excluded from the PP set for not achieving the minimum
treatment duration of 24 weeks (n¼134); 57 of them dropped
out in the ﬁrst 6 weeks. This protocol violation had been
predeﬁned to generate information about seizure freedom in
a patient collective compliant to longer term medication. On
comparing proportions of seizure-free patients in the analysis
sets, no difference in seizure freedom between patients with
short time and longer time medication could be found.
Furthermore, the ITT and the PP analyses for the primary
endpoint led to identical results regarding risk ratios and risk
differences (see table 2). Therefore, it is unlikely, that the
protocol violation rate did inﬂuence the results of the primary
endpoint.
Our subgroup analyses, considering age groups, epilepsy
syndrome and the diagnosis of epilepsy versus a ﬁrst seizure
with high recurrence risk, showed no differences regarding the
efﬁcacy of the two drugs compared. However, seizure recurrence
rates varied among subgroups. It was signiﬁcantly lower in
patients with a ﬁrst seizure associated with high risk of recur-
rence as compared with those patients fulﬁlling the classic
deﬁnition of epilepsy (occurrence of two or more unprovoked
seizures). This ﬁnding lends further support to the view to
consider these two groups separately,14 especially when plan-
ning studies of newly diagnosed epilepsy in the future.
Furthermore, the likelihood of seizure recurrence was related to
age, highest in patients under 18 years and lowest in older
patients. Surprisingly, recurrence rate was similar in patients
with focal as compared with generalised and unclassiﬁed
epilepsy syndromes.
Retention was identical in both arms during the ﬁrst 6 weeks
and started to separate in week 7, being non-signiﬁcantly lower
in the LEV arm later on. Lack of retention was due to lack of
tolerability rather than due to lack of efﬁcacy and AEs leading to
discontinuation were non-signiﬁcantly more frequent in the
LEV arm. Tiredness and aggression were more frequent in
the LEVarm while rash and nausea were twice as frequent in the
LTG arm, conﬁrming the side-effect proﬁle of the two drugs
revealed in the regulatory trials9 20e26 and clinical practiceddata
which may help counselling patients regarding the choice of the
initial monotherapy. It is possible that side effects would be less
prominent if extended release formulations were used.
QoL did not change over the treatment period in both arms.
These ﬁndings were concordant with results of previously
published studies where seizure frequency, but not duration of
epilepsy, was associated with a poorer outcome in QoL.27
Furthermore, 26 weeks may well be too short to allow for an
improvement in QoL because driving restrictions persisted in the
majority of the patients and this interval is probably too short to
experience reliable seizure control.
The clinical implications of the results of this trial are that
a more rapid titration does not necessarily translate into a clini-
cally relevant reduction in the rate of early recurrence, especially
when considering initial monotherapy in a population with
a relatively low risk of recurrence. This may, however, be
different in patients with a high initial seizure frequency. Our
study failed to prove superiority of LEV over LTG regarding
seizure freedom at 6 weeks after initiation of treatment. Since it
was not designed to provide data regarding non-inferiority, this
needs to be investigated by further studies.
The decision to include patients with a single seizure and
a high risk of seizure recurrence as deﬁned in the proposal of the
International League Against Epilepsy and International Bureau
for Epilepsy, in 2005,16 is a pragmatic approach and reﬂects
current clinical practice. It has been shown, for instance, that
94% of patients with a cavernoma and a ﬁrst seizure will have
a recurrence28 and, therefore, it would be unjustiﬁed to deny
anticonvulsive treatment in such circumstances.
The risk of this approach is an overtreatment of patients in
cases with benign syndromes and very low recurrence risk,
where an anticonvulsive treatment might not be necessary.
Therefore, the deﬁnition of an ‘enduring alteration of the brain
that increases the likelihood of future seizures’16 used in the new
proposal had to be considered carefully. It includes cases with
a lesion on brain imaging, a focal neurological deﬁcit, a focal ictal
symptomatology or a pathological EEG.14 15 As epileptiform and
non-epileptiform EEG abnormalities have been identiﬁed as
predictors for seizure recurrence,29 30 we included both types of
abnormalities in our inclusion criteria. Of interest, using the new
deﬁnition of epilepsy our study provided evidence that the
seizure recurrence rates in patients with a ﬁrst seizure only is
lower, suggesting that in future clinical trials on newly diag-
nosed epilepsy, patients should be stratiﬁed depending on
whether or not the new deﬁnition of epilepsy is applied.
Author affiliations
1Department of Neurology, Epilepsy Center Hessen, University Hospitals Giessen &
Marburg and Philipps-University Marburg, Germany
2Coordinating Center for Clinical Trials (KKS), Philipps-University Marburg, Marburg,
Germany
3Department of Neurology, University of Ulm, Ulm, Germany
4Department of Neurology and Epileptology, University Hospital Tuebingen, Tuebingen,
Germany
5Department of Neurology, University of Mu¨nster, Mu¨nster, Germany
6Department of Neurology, University of Dresden, Dresden, Germany
7Department of Neurology, Leopoldina Hospital, Schweinfurt, Germany
8Private Neurological Practice, Westerstede, Germany
9Private Neurological Practice, Oldenburg, Germany
10Private Neurological Practice, Lich, Germany
11Private Neurological Practice, Munich, Germany
12Department of Neurology, District Hospital Altenburg, Altenburg, Germany
13Department of Neurology, University of Regensburg, Regensburg, Germany
14Private Neurological Practice, Munich, Germany
Acknowledgements We would like to thank UCB Pharma for the generous
support of our study. We are indebted to the patients for giving their informed
consent to participate in the study and for their cooperation throughout the study.
Contributors FR, HMH and CS-B designed the study and wrote the study protocol.
CS-B, FR and NB drafted and amended the statistical analysis plan and NB was
Table 3 Most common adverse events (events counted once per
patient)
LEV (n[204) LTG (n[201) Total (n[405) LEV vs LTG
n (%) n (%) n (%) p Value*
Tiredness 67 (32.8) 33 (16.4) 100 (24.7) <0.001
Headache 47 (23.0) 56 (27.9) 103 (25.4) 0.47
Vertigo 35 (17.2) 39 (19.4) 74 (18.3) 0.72
URTI 35 (17.2) 27 (13.4) 62 (15.3) 0.34
Sleep disorder 22 (10.8) 33 (16.4) 55 (13.6) 0.17
Aggression 18 (8.8) 5 (2.5) 23 (5.7) 0.006
Depression 10 (4.9) 6 (3.0) 16 (4.0) 0.32
Asthenia 10 (4.9) 8 (4.0) 18 (4.4) 0.64
Rash 9 (4.4) 19 (9.5) 28 (6.9) 0.08
Nausea 9 (4.4) 19 (9.5) 28 (6.9) 0.08
Diarrhoea 6 (2.9) 10 (5.0) 16 (4.0) 0.45
Tremor 6 (2.9) 15 (7.5) 21 (5.2) 0.08
p-values below 0.05 in the descriptive statistics are written in bold.
*c2 test.
LEV, levetiracetam; LTG, lamotrigine; URTI, upper respiratory tract infection.
Epilepsy
J Neurol Neurosurg Psychiatry 2012;83:1093–1098. doi:10.1136/jnnp-2012-301999 1097
group.bmj.com on September 5, 2017 - Published by http://jnnp.bmj.com/Downloaded from 
responsible for the biometrical analyses in the study. FR, CS-B, HMH and AH reviewed
the statistical analysis. FR, SB, KMK, YW, HL, SA, AB, SE, SK, S-HE, GW, JS, MN, ER,
IE, JB, MS, AS and PSR had initially approved the protocol and were actively involved
in patient recruitment and data collection. SB and PSR were actively involved in data
quality assurance and monitoring. FR, NB, CS-B, HMH, WHO, PSR and AS actively
contributed to the writing and reviewing of the submitted manuscript. All authors
reviewed the manuscript and approved the final version.
Funding UCB Pharma was involved in the study design and provided personnel for
regular monitoring visits. UCB Pharma was not involved in data analysis, interpretation
of the data and in the decision to submit the paper for publication.
Competing interests This study was sponsored by Philipps-University Marburg,
Marburg, Germany. UCB Pharma provided the majority of the funding. Several of the
authors have received honoraria and research and travel grants from UCB Pharma, the
producer of LEV, and GSK the original producer of LTG.
Ethics approval This study was approved by the ethics committee of the University
of Marburg, Germany.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement For data sharing requests please contact FR (rosenow@
med.uni-marburg.de).
REFERENCES
1. Forsgren L, Beghi E, Oun A, et al. The epidemiology of epilepsy in Europe -
a systematic review. Eur J Neurol 2005;12:245e53.
2. King MA, Newton MR, Jackson GD, et al. Epileptology of the first-seizure
presentation: a clinical, electroencephalographic, and magnetic resonance imaging
study of 300 consecutive patients. Lancet 1998;352:1007e11.
3. Anon. Considerations on designing clinical trials to evaluate the
place of new antiepileptic drugs in the treatment of newly
diagnosed and chronic patients with epilepsy. Epilepsia
1998;39:799e803.
4. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med
2000;342:314e19.
5. Anon. Prognostic index for recurrence of seizures after remission
of epilepsy. Medical Research Council Antiepileptic Drug
Withdrawal Study Group. BMJ 1993;306:1374e8.
6. Specchio LM, Tramacere L, La Neve A, et al. Discontinuing antiepileptic drugs in
patients who are seizure free on monotherapy. J Neurol Neurosurg Psychiatry
2002;72:22e5.
7. Marson AG, Al-Kharusi AM, Alwaidh M, et al; SANAD Study group. The SANAD
study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or
topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.
Lancet 2007;369:1000e15.
8. Marson AG, Al-Kharusi AM, Alwaidh M, et al; SANAD Study group. The SANAD
study of effectiveness of valproate, lamotrigine, or topiramate for generalised and
unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet
2007;369:1016e26.
9. Brodie MJ, Perucca E, Ryvlin P, et al; Levetiracetam Monotherapy Study Group.
Comparison of levetiracetam and controlled-release carbamazepine in newly
diagnosed epilepsy. Neurology 2007;68:402e8.
10. Pohlmann-Eden B, van Paesschen W, Hallstro¨m Y, et al. The KOMET study: an
open-label, randomized, parallel-group trial comparing the efficacy and safety of
levetiracetam with sodium valproate and carbamazepine as monotherapy in subjects
with newly diagnosed epilepsy. Epilepsia 2008;49(Suppl 7):448e9.
11. Drazkowski J. An overview of epilepsy and driving. Epilepsia 2007;48(Suppl
9):10e12.
12. Smeets VM, van Lierop BA, Vanhoutvin JP, et al. Epilepsy and employment:
literature review. Epilepsy Behav 2007;10:354e62.
13. Strzelczyk A, Reese JP, Dodel R, et al. Cost of epilepsy: a systematic review.
Pharmacoeconomics 2008;26:463e76.
14. Haut S, O’Dell C, Shinnar S. Risk factors for developing epilepsy after a first
unprovoked seizure. In: Ryvlin P, ed. From First Unprovoked Seizure to Newly
Diagnosed Epilepsy. Montrouge, France: John Libbey Eurotext, 2007:37e48.
15. Kim LG, Johnson TL, Marson AG, et al. Prediction of risk of seizure recurrence after
a single seizure and early epilepsy: further results from the MESS trial. Lancet Neurol
2006;5:317e22.
16. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy:
definitions proposed by the International League Against Epilepsy (ILAE) and the
International Bureau for Epilepsy (IBE). Epilepsia 2005;46:470e2.
17. Cramer JA, Arrigo C, Van Hammee G, et al. Comparison between the QOLIE-31 and
derived QOLIE-10 in a clinical trial of levetiracetam. Epilepsy Res 2000;41:29e38.
18. Cramer JA, Perrine K, Devinsky O, et al. A brief questionnaire to screen for quality of
life in epilepsy: the QOLIE-10. Epilepsia 1996;37:577e82.
19. Brodie MJ, Chadwick DW, Anhut H, et al. Gabapentin versus lamotrigine
monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia
2002;43:993e1000.
20. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised
comparison between lamotrigine and carbamazepine in elderly patients with newly
diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res
1999;37:81e7.
21. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and
carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine
Monotherapy Trial Group. Lancet 1995;345:476e9.
22. Chaisewikul R, Privitera MD, Hutton JL, et al. Levetiracetam add-on for drug-
resistant localization related (partial) epilepsy. Cochrane Database Syst Rev 2001;(1):
CD001901.
23. Gamble CL, Williamson PR, Marson AG. Lamotrigine versus carbamazepine
monotherapy for epilepsy. Cochrane Database Syst Rev 2006;(1):CD001031.
24. Labiner DM, Ettinger AB, Fakhoury TA, et al. Effects of lamotrigine compared with
levetiracetam on anger, hostility, and total mood in patients with partial epilepsy.
Epilepsia 2009;50:434e42.
25. Reunanen M, Dam M, Yuen AW. A randomised open multicentre comparative trial
of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed
or recurrent epilepsy. Epilepsy Res 1996;23:149e55.
26. Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine monotherapy in newly
diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia
1999;40:601e7.
27. Guekht AB, Mitrokhina TV, Lebedeva AV, et al. Factors influencing on quality of life
in people with epilepsy. Seizure 2007;16:128e33.
28. Josephson CB, Leach JP, Duncan R, et al; Scottish Audit of Intracranial Vascular
Malformations (SAIVMs) steering committee and collaborators. Seizure risk from
cavernous or arteriovenous malformations: prospective population-based study.
Neurology 2011;76:1548e54.
29. Shinnar S, Berg AT, Moshe SL, et al. The risk of seizure recurrence after a first
unprovoked afebrile seizure in childhood: an extended follow-up. Pediatrics
1996;98:216e25.
30. Shinnar S, Kang H, Berg AT, et al. EEG abnormalities in children with a first
unprovoked seizure. Epilepsia 1994;35:471e6.
APPENDIX 1
The LaLiMo Study Group
Principal investigators (all Germany): S Arnold (Mu¨nchen), J Berrouschot (Alten-
burg), U Bongartz (Ko¨ln), J Claßen (Wu¨rzburg), S Dorfmu¨ller (Schopfheim), I Eisensehr
(Mu¨nchen), S Evers (Mu¨nster), V Fischer (Neunkirchen), T Freudenberger (Traunstein),
CG Haase (Recklinghausen), W Heide (Celle), H Hielscher (Gelsenkirchen), WE
Hofmann (Aschaffenburg), U Hoot (Wismar), S Jackowski-Dohrmann (Marburg), P
Kalischewski (Leipzig), M Kieslich (Frankfurt), G Kirn (Gladenbach), M Klein (Wu¨rz-
burg), J Klingelho¨fer (Chemnitz), I Klyk (Ru¨sselsheim), A Kowalik (Stuttgart), T Krohn
(Wismar), G Kurlemann (Mu¨nster), M Lang (Ulm), U Loel (Salzgitter), G Mayer
(Schwalmstadt), H Molitor (Wu¨rzburg), W Molt (Stuttgart), B Neubauer (Gießen), M
Niedhammer (Oldenburg), H Pausch (Marburg), C Pilz (Mannheim), U Reuner
(Dresden), N Rigas (Berlin), K Roch (Zwickau), F Rosenow (Marburg), E Roth (Lich), K
Ru¨ther (Oberursel), G Schmidt (Ludwigsfelde), M Schro¨der (Regensburg), A Simonow
(Herborn), J Springub (Westerstede), D Sta¨dt (Lohr), H Stefan (Erlangen), C Stenzel
(Ko¨ln-Rodenkirchen), F Sto¨gbauer (Osnabru¨ck), I Su¨nkeler (Braunfels), U Thumulla
(Salzgitter), R Trollmann (Erlangen), S Unglaub (Frankfurt), T Vetter (Schkeuditz), Y
Weber (Ulm), B Wild (Nagold), G Winkler (Schweinfurt), A Wirbatz (Gießen), E
Wollenhaupt (Dresden), U Zimmerer (Ludwigshafen).
Steering Committee: Bernd A Neubauer (Giessen), Heinz Reichmann (Dresden),
Felix Rosenow (Marburg).
Independent Safety Advisory Board (ISAB): Gu¨nter Kra¨mer (Zurich), Peter
Martus (Berlin), Bernhard J Steinhoff (Kork).
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